Long-Term Outcomes in Hodgkin Lymphoma: The Impact of Initial Therapy

Ten-year survival was similar with ABVD or BEACOPP, but BEACOPP was associated with a high rate of late second malignancies.

Maintaining high cure rates while lowering early and late treatment-related toxicity remains a challenge for patients with advanced-stage Hodgkin lymphoma.

Now, Italian investigators have performed a post-hoc analysis of long-term outcomes from a prospective, multicenter, randomized phase III trial of 305 evaluable patients who received induction therapy with one of three regimens: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), or COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin).

At a median follow-up of 10 years, no …

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Long-Term Outcomes in Hodgkin Lymphoma: The Impact of Initial Therapy

Topics

Reviewing Author